BTMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BTMD is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act immediately. The stock has weak near-term momentum, recent earnings declines, and no proprietary buy signal. While insiders are buying and management still expects full-year revenue and EBITDA growth targets, the current setup is better suited to a wait-and-watch approach than an immediate long-term purchase.
BTMD is trading at 2.10, essentially flat versus the prior close of 2.09, but the broader summary also notes a -5.00% regular market move, showing weak tape. The MACD histogram is -0.0184 and negatively expanding, which is bearish. RSI_6 at 38.19 is not oversold enough to signal a clear rebound, and moving averages are converging, indicating a lack of trend strength. Price is below the pivot resistance zone (2.168), with support near 2.031 and 1.946. Overall, the chart shows weak short-term momentum and no confirmed uptrend.
Management maintained full-year targets of over $190 million in revenue and more than $38 million in adjusted EBITDA. Analysts still include Buy ratings from Truist, Roth Capital, and TD Cowen, suggesting some belief in a recovery later in 2026.
Q1 2026 revenue fell 8.3% year over year to $44.9 million due to a voluntary recall. Net income dropped 83.4% and EPS fell 86.4%, showing significant profitability pressure. Gross margin also declined to 68.88%. Management admitted the recall distracted the sales team and reduced first-half procedure revenue expectations. Recent analyst target cuts and one Neutral rating from B. Riley reflect continued caution, and the stock has no AI Stock Picker or SwingMax signal today.
In Q1 2026, Biote reported revenue of $44.9 million, down 8.28% year over year. Net income fell to $2.28 million, down 83.40% YoY, and EPS declined to $0.06, down 86.36% YoY. Gross margin was 68.88%, down 7.24% YoY. The latest quarter season is Q1 2026, and the results show clear top-line and bottom-line pressure despite management keeping its full-year guidance intact.
Recent analyst sentiment is mixed to cautious. Truist cut its target to $4 from $5 but kept Buy. B. Riley cut its target to $2 from $3 and kept Neutral after Q4. Roth Capital lowered its target to $3 from $4.50 and kept Buy, while TD Cowen cut to $2.50 from $3 and kept Buy. The overall Wall Street view is cautiously constructive on the long term, but near-term upside looks limited because multiple firms reduced targets and cited execution, recall, and growth timing issues.
